A research study investigating the use of magic mushrooms in Canada revealed that nearly 80% of participants support the availability of psilocybin as a medical treatment for distressed patients. Moreover, about two-thirds of Canadian respondents from the same study concurred that psilocybin should be legally available to those in need.
Beyond advocating for easier access to the substance, a significant 84.8 percent of participants expressed their belief that the public health system should bear the costs of such therapies. A majority of Canadians perceive psilocybin as a feasible solution, particularly for treating end-of-life distress.
[toc]
Main Takeaways:
- Residents of Québec, Ontario, Alberta, and British Columbia acknowledge psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Existential distress can safely be treated with magic mushrooms.
- Participants in two double-blind trials reported immediate and lasting benefits, with effects enduring six months or even longer.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their mortality. Such patients may grapple with feelings of despair, isolation, anxiety, and a loss of purpose and meaning. This form of distress notably affects patients with life-threatening illnesses, possibly leading to a wish for hastened death or suicidal contemplation.
Individuals facing terminal illnesses or major life changes are typically the ones who experience this type of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to address problems such as anxiety, depression, grief, loneliness, indifference, despair, identity confusion, feelings of purposelessness, and existential fear. It often requires several sessions and may not be beneficial for everyone.
The uncertainty surrounding the effectiveness of such therapy is a key reason why many individuals seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in the treatment of complex mental disorders. Specifically, Psilocybin has demonstrated a quick and sustained reduction of existential distress in patients nearing their life’s end.
Recognizing the possible efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadians’ Advocacy for Psilocybin Access
A study published in the Palliative Care Journal examines societal views on psilocybin-facilitated therapy for end-of-life care. The data collected in the study includes:
| Method | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants had prior experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Results | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% advocate for the public health system to provide this therapy. 44.2% believe healthcare professionals should administer the substance without the supervision of Health Canada. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers emphasized the uniqueness of their study, as it focuses on the use of psychoactive substances to address existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are endorsing the use of psilocybin as a treatment, primarily driven by the findings of esteemed research institutions. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. No severe negative health outcomes, such as multi-organ failure, have been reported by participants in various studies.
| Research | Method | Results |
| Johns Hopkins Study | 51 patients were provided with a high dose of psilocybin and a low dose as an active control | Immediate and sustained |
| The benefits can last up to six months or even longer. The effectiveness of the therapy is primarily attributed to mystical experiences that are characterized by a profound sense of unity and deep emotional insights. | ||
| Trial at New York University | 29 patients were randomly assigned to either receive psilocybin or the active placebo, niacin. | The results of the study reflected those of the Johns Hopkins study. Participants that were administered psilocybin reported experiencing psychological relief and a new outlook on life and death. |
| BMC Palliative Care | A group of nineteen participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The objective of the study was to comprehend how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a treatment option. | Palliative care practitioners believe that psychedelic-assisted therapy (PAT) has potential to alleviate existential distress. |
Patient Experiences
Apart from scientific studies, several patient testimonials also emphasize the effectiveness of psilocybin in improving mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares her transformative experience during her assisted therapy. She visualizes being on a raft, surrounded by nature, and in the company of whimsical creatures. This vision instills in her a deep recognition of the universe’s interconnectedness and support, leading to immense peace and affirmation.
Despite conventional mental health support, Yokoi’s intense anxiety and distress persisted after her diagnosis. Psilocybin therapy allowed her to reconnect with her body, and provided a tangible sense of love and support. This significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was an administrative supervisor in healthcare working full-time when the study was conducted. Chrissy identified as an atheist and was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced notable reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs post-therapy, she stated that the experiences added depth and authenticity to her beliefs.
The Experience of Brenda
Brenda, a woman in her mid-sixties, was diagnosed with Stage I colon cancer. She was found to be a non-user of hallucinogens during her screenings and was further diagnosed with Chronic Adjustment Disorder, which was accompanied by anxiety.
Throughout her therapeutic sessions, Brenda encountered the sensation of death twice. Yet, instead of fear, she came out with a newfound acceptance of death, viewing it as a natural part of the life cycle. She credits the study as the catalyst for her healing process from past childhood trauma. Her data reflected this profound change.
It was observed that her fear of death and anxiety was significantly diminished, while her spirituality was notably enhanced.
Assortment of Psilocybin Products in Canada
At present, the access to psilocybin capsules and other similar products intended to alleviate existential distress or other mental health conditions may be limited. However, reliable online dispensaries serve as an excellent resource for obtaining these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some adjacent South American countries. | Discovered in Cambodia, specifically around the Angkor Wat Temple. | Linked to the Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Moderate potency as well; perfect for novices. | Extremely potent; advised for those with intermediate to advanced experience. |
| Effects | Triggers a mental buzz, mild disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved concentration. | Induces an energizing and lasting high, minor visual changes, heightened creativity, euphoria, a smooth physical sensation, fractal imagery, and feelings of happiness. | Generates profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, concentration, social awareness, and mood enhancement. |
Mitigate End-of-life Anxiety with Psilocybin Products
Existential or end-of-life anxiety can put immense pressure on many individuals as they approach the end of their lives. Conventional treatments may not always be effective in managing this anxiety, leading to a surge in Canadian advocacy for more accessible magic mushrooms in public healthcare. This growing public interest could
We urge regulatory authorities to recognize magic mushrooms as a potential treatment option. Get your psychedelics and shroom delivery from Magic Mushrooms Montreal Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences of patients with Psychedelic-assisted therapy (PAT) can greatly differ, making meticulous preparation and adherence to certain steps crucial for a positive outcome. Patients must undergo thorough screening and mental preparation prior to consuming the substance.
- Preparation before the Session: Patients undergo a comprehensive assessment. The therapist delves into the patient’s goals and expectations to set intentions for the session. The therapist also informs the patient about the effects of the process and what to expect during the session.
- The Session: The substance is given to patients in controlled doses during the session, which is held in a comfortable, distraction-free environment to foster relaxation and self-reflection. The therapist remains present throughout for continuous support and guidance.
- Post-Session Integration Therapy: This therapy helps the patient interpret and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, particularly the 5-HT2A receptor. This interaction can trigger changes in perception, mood, and cognition, leading to profound alterations in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not suitable for everyone. Individuals with certain mental health issues or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
